Skip to main content

Table 5 Comparison of the clinical evaluation

From: A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients

 

Pleural fluid

Plasma

 

Sequencing

ADx-ARMS

Sequencing

ADx-ARMS

Mutation

positive

Number (%)

16(50%)

22(68.8%)

0

5(27.8%)

 

PR

13

16

0

4

 

SD

2

5

0

0

 

PD

1

1

0

1

 

ORR

81.3%a

72.7%c

NA

80%e

Mutation negative

Number (%)

16(50%)

10(31.2%)

18(100%)

13(72.2%)

 

PR

9

6

10

6

 

SD

4

1

1

1

 

PD

3

3

7

6

 

ORR

56.3%b

60%d

55.6%

46.2%f

  1. PR = Partial Response; SD = Stable Disease; PD = Progressive Disease; ORR = Objective response rate
  2. Between a and b, P = 0.2524; Between c and d, P = 0.6828; Between e and f, P = 0.3137; Between a and c, P = 0.706